NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
100
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,300.23 | 91.76 | 0.20% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,842.29 | 104.47 | -0.48% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 288.24 | -2.22% |
| S&P 500 | 6,578.71 | 2.29 | -0.03% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |